Furthermore, patients with low UGP2 expression had significantly poorer prognoses across several subgroups, including those with pathological T3 and T4 stages, pathological M1 stage, and pathological stages II, III, and IV, female patients, those aged ≤65 years, and those with no history of colon polyps, no lymphatic invasion, and no perineural invasion, than those with high UGP2 expression (Figure 5D–L). Here, UGP2 is linked to intestinal disorder.